First, we have conducted a subgroup analysis of multiple tumor types to assess potential sources of heterogeneity, but we are unable to carry out hierarchical analysis on patients based on baseline information (age, stage at diagnosis, tumor size, grade, or NAT). This evidence concerns the gene BRD2 and neoplasm.